drugset

drugset / Trial / NCT01959295

Phase III Study of ASP2151 in Herpes Simplex Patients

NCT01959295 ↗

Phase 3 Completed 468 enrolled Maruho Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.

Timeline

Start: 2013-08
Primary completion: 2015-04
Completion: 2015-04-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amenamevir	Small molecule	200 mg	—

Indications